Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing. According to the company, this creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO). Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. In addition to its directly owned drug pipeline, the company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
The completion of Phase 2 objectives marks a significant step toward commercializing AI-driven automation in pharmaceutical manufacturing. For industry leaders, this development signals the growing integration of artificial intelligence and robotics in GMP environments, potentially reducing costs, improving quality, and accelerating production timelines. Oncotelic's platform could offer a scalable solution for sterile injectable manufacturing, a critical area with high regulatory standards. The company's planned demonstration at BIO 2026 will likely attract attention from pharmaceutical companies seeking to modernize their manufacturing capabilities.
For more information, visit https://nnw.fm/j1n43 and the company's newsroom at https://nnw.fm/OTLC.
